Abhilash Makkar, MD
Hospitalist · Oklahoma City, OKNPI 1750603270
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Johnson & Johnson at 25.0% of the total. 2024 is the largest year on record at $264, more than ten times the $18 reported in 2021.
Across 20 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$97
- Gilead$83
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$53
- Ceribell, Inc.$41
- Inari Medical, Inc.$28
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$21
- plus $64 from 4 others
What the payments were for
- Food & beverage$387100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 5 | $97 |
| Gilead | 5 | $83 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Ceribell, Inc. | 1 | $41 |
| Inari Medical, Inc. | 1 | $28 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| AstraZeneca | 1 | $18 |
| Pfizer | 1 | $17 |
| Merck | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
How this compares
$387 in reported general payments places this provider in the 80th percentile of 234 hospitalist providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefdinir | 38 | $460 |
| Doxycycline Hyclate | 33 | $284 |
| Levofloxacin | 21 | $148 |
| Cephalexin | 17 | $140 |
| Hydralazine Hcl | 15 | $131 |
| Amlodipine Besylate | 21 | $130 |
| Pantoprazole Sodium | 25 | $84 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $76 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $73 |
| Ciprofloxacin Hcl | 14 | $70 |
| Prednisone | 28 | $59 |
| Azithromycin | 14 | $17 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Oklahoma City
- Zubair AshrafOklahoma City$4K
- Steven DanleyOklahoma City$2K
- Timothy CookOklahoma City$2K
- Marcus ToschiOklahoma City$616
- David AbernethyOklahoma City$588
- Saqib SheikhOklahoma City$442
- Senthil RajuOklahoma City$437
- Abdul FtesiOklahoma City$373
- Angela HawkinsOklahoma City$369
- Syed QuadriOklahoma City$303
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.